sublingual misoprostol 25 µg and oral misoprostol 50 µg on reducing post-term pregnancy

The effect of outpatient sublingual misoprostol 25 µg and oral misoprostol 50 µg on reducing post-term pregnancy and induction success and evaluation of maternal and fetal outcomes: a double-blind clinical trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191208045653N1

Enrollment

140

Registered

2020-02-14

Start date

2019-12-04

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

termination of pregnancy. Medical abortion

Interventions

Intervention 1: Intervention group: Misoprostol tablets 25 micrograms sublingual. Intervention 2: Control group: Misoprostol 50 mg oral tablets.

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Maximum gestational age of 40 weeks pregnant women Prime Grave Single pregnancy Cephalic display Having normal amniotic fluid (AFI greater than or equal to 5 cm) Bishop Score less than 8 Maternal age between 18 and 40 years

Exclusion criteria

Exclusion criteria: History of medical and midwifery disease Diabetes Preeclampsia History of stillbirth Opt out of the study Improper use of medication

Design outcomes

Primary

Measure	Time frame
Duration of Cervical Preparation to Delivery. Timepoint: After Intervention. Method of measurement: Time.	—

Secondary

Measure	Time frame
Fetal heart monitoring. Timepoint: After intervention. Method of measurement: Cardiac monitoring device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Partanezhad

Mashhad University of Medical Sciences

Partans941@mums.ac.ir+98 51 3801 2611

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026